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Research on the adverse effects of lead exposure
on humans has focused on neurocognitive out-
comes among children [Canﬁeld et al. 2003;
National Research Council (NRC) 1993].
However, a growing body of literature reports
that the effects of childhood lead exposure con-
tinue into adolescence and adulthood. These
include delinquent behavior (Dietrich et al.
2001; Needleman et al. 2002), dental caries
(Moss et al. 1999), hypertension (Hu et al.
1996; Nash et al. 2003), cardiac arrhythmias
(Cheng et al. 1998), and renal dysfunction
(Kim et al. 1996). Research also demonstrates
another potential late effect of childhood lead
exposure: osteoporosis. Studies on rats have
found that increased lead exposure is associated
with decreased bone density (Escribano et al.
1997; Gruber et al. 1997; Puzas et al. 1999)
and decreased bone strength (Ronis et al.
2001). Additional studies have found that lead
exposure inhibits the function of osteoblasts
(Klein and Wiren 1993; Puzas et al. 1999;
Ronis et al. 2001), the cells that make bone.
However, human studies on this asso-
ciation are limited. In a study of children,
Laraque et al. (1990) found no association
between bone density and lead exposure.
However, because the comparison group was
made up of children with moderate-level lead
exposure (i.e., blood lead level 12–29 µg/dL),
such a study cannot exclude the possibility
that lead exposure has an effect at lower levels.
In addition, because the children were exam-
ined at a young age (range, 18–47 months),
sufficient time may not have elapsed for the
adverse effects on the bone to become mani-
fest. A study by Alfvén et al. (2002) also found
no association between lead exposure and bone
mineral density (BMD) in a cross-sectional
study of adults. However, the authors used
concurrent blood lead level to define lead
exposure and acknowledged that such a meas-
ure may be inadequate to measure body lead
burden. In addition, subjects did not have
high blood lead levels [the mean blood lead
level was 3.1 µg/dL (Alfvén T, personal com-
munication)]; thus, the lack of an association
may be due to low lead exposure among
the subjects.
Our objective was to determine whether
an association between lead exposure and bone
density exists in children. We hypothesized
that the bone density of children with high
lead exposure would be lower than the bone
density of children with low lead exposure.
Materials and Methods
Subject identification and enrollment. To
identify potential subjects who had an ade-
quate number of blood lead levels to define
past lead exposure, we obtained a comprehen-
sive database of blood lead levels from the
local county health department (Department
of Health, Monroe County, New York State).
To minimize the effect of age on BMD, we
limited the database to children 8–10 years of
age. In the database, we excluded capillary
blood lead levels ≥ 10 µg/dL, because of the
possibility that these represent contaminated
specimens [Centers for Disease Control and
Prevention (CDC) 1991], and children who
did not have at least one blood lead level at
each of four age groups (13–24 months,
25–36 months, 37–48 months, and 49–60
months). For the remaining children, we cal-
culated each child’s cumulative lead exposure
(defined below) and created a list with the
following information: child’s name, date of
birth, race, and cumulative lead exposure.
From the list, we identified children who
attended the principal investigator’s (J.R.C.)
pediatric practice or whom the principal
investigator had medically managed for lead
toxicity. To eliminate the effect of race, we
contacted only subjects who were African
American. The principal investigator (J.R.C.)
subsequently called the parents of the potential
subjects to ask if they would be interested in
having the child enrolled. If a parent agreed, a
short questionnaire was administered to deter-
mine whether exclusionary criteria existed. We
excluded children who had medical condi-
tions that affected bone density (metabolic
bone disease, renal disease, sickle cell disease),
used certain medications (corticosteroids,
anticonvulsants, diuretics), had evidence of
sexual maturation (i.e., Tanner stage ≥ 2), or
had a parent who was not African American.
If no exclusionary criteria existed, the study
coordinator (L.N.) called the parent to sched-
ule an appointment for the bone density
procedure. At the appointment, the study
coordinator obtained informed consent, com-
pleted a questionnaire to collect covariate
date, and measured the child’s height and
weight. Subsequently, one technician con-
ducted the bone density measurement. The
study coordinator and technician were
blinded to the subject’s cumulative lead
exposure status.
The Human Subjects Committee of
the Monroe County Health Department,
Address correspondence to J.R. Campbell, Department
of Pediatrics, MOB Suite 300, Rochester General
Hospital, 1425 Portland Ave., Rochester, NY 14621
USA. Telephone: (585) 922-3919. Fax: (585) 922-
3929. E-mail: James.Campbell@ViaHealth.org
We thank C. Muzytchuk for conducting the bone
density measures, and R. O’Keefe, M. Zuscik, and
S. Schaffer for their thoughtful commentary on the
manuscript.
This work was supported by University of
Rochester Environmental Health Sciences Center
grants NIEHS P30 ES01247 and NIEHS PO1
ES011854.
The authors declare they have no competing
ﬁnancial interests.
Received 30 June 2003; accepted 7 April 2004.
The Association between Environmental Lead Exposure and Bone Density
in Children
James R. Campbell,1 Randy N. Rosier,2 Leonore Novotny,2 and J. Edward Puzas2
1Department of Pediatrics and 2Department of Orthopedics, University of Rochester Medical Center, Rochester, New York, USA
Osteoporosis is a decrease in bone mineral density (BMD) that predisposes individuals to
fractures. Although an elderly afﬂiction, a predisposition may develop during adolescence if a suf-
ficient peak BMD is not achieved. Rat studies have found that lead exposure is associated with
decreased BMD. However, human studies are limited. We hypothesized that the BMD of children
with high lead exposure would be lower than the BMD of children with low lead exposure. We
collected data on 35 subjects; 16 had low cumulative lead exposure (mean, 6.5 µg/dL), and 19 had
high exposure (mean, 23.6 µg/dL). All were African American; there was no difference between
the groups by sex, age, body mass index, socioeconomic status, physical activity, or calcium intake.
Signiﬁcant differences in BMD between low and high cumulative lead exposure were noted in the
head (1.589 vs. 1.721 g/cm2), third lumbar vertebra (0.761 vs. 0.819 g/cm2), and fourth lumbar
vertebra (0.712 vs. 0.789 g/cm2). Contrary to our hypothesis, subjects with high lead exposure
had a signiﬁcantly higher BMD than did subjects with low lead exposure. This may reﬂect a true
phenomenon because lead exposure has been reported to accelerate bony maturation by inhibiting
the effects of parathyroid hormone–related peptide. Accelerated maturation of bone may ulti-
mately result in a lower peak BMD being achieved in young adulthood, thus predisposing to
osteoporosis in later life. Future studies need to investigate this proposed model. Key words: blood
lead levels, bone mineral density, dual-energy X-ray absorptiometry, parathyroid hormone–related
peptide. Environ Health Perspect 112:1200–1203 (2004). doi:10.1289/ehp.6555 available via
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Measure of lead exposure. The measure of
lead exposure used in this study is termed the
cumulative lead exposure. To compute it, we
identiﬁed all blood lead levels collected during
four age strata (i.e., 12–23 months, 24–35
months, 36–47 months, and 48–60 months)
from the local health department database.
Subsequently, we calculated the arithmetic
mean of all blood lead levels for each of the
four age strata. Finally, the cumulative lead
exposure was calculated by computing the
arithmetic mean of the four age strata means.
Subjects were dichotomized as having high
versus low cumulative lead exposure at a cutoff
of 15 µg/dL.
There is a strong correlation (i.e.,
0.92–0.95) between any single blood lead level
in children between 2 and 4 years of age and
cumulative lead exposure measure based on
24 serial blood lead levels in children between
3 months and 10 years of age (Dietrich K,
personal communication); therefore, we con-
clude that our measure of cumulative lead
exposure is a valid measure of the overall life-
time lead exposure for a school-age child.
Measure of bone density. We used a
fan-beam dual-energy X-ray absorptiometry
(DEXA) scanner (Prodigy; GE/Lunar Cor-
poration, Madison, WI) to measure BMD
(Mazess et al. 1990). BMD was determined at
various body regions (e.g., total body, arms,
legs, trunk), the lumbar vertebrae, and hip
regions (total hip, femoral neck, trochanter,
femoral shaft).
Measure of covariates. Variables associated
with changes in bone density include age (Boot
et al. 1997; Maynard et al. 1998), race (Nelson
et al. 1997; Pollitzer and Anderson 1989),
weight (Boot et al. 1997), physical activity
(Cooper et al. 1988), and calcium intake
(Johnston et al. 1992). Bone density does not
vary by sex among children < 13 years of age
(Maynard et al. 1998).
To minimize the effect of age, we enrolled
only subjects within a narrow age range:
8–10 years. To eliminate the effect of race, we
enrolled only subjects who were African
American (and whose parents were both
African American). We measured subject
weight and height at the time of the BMD
measurement. A parental questionnaire col-
lected data on physical activity (i.e., the num-
ber of hours a day the child is physically active
and inactive), calcium intake (i.e., current
milk and milk-product intake and frequency),
and socioeconomic status [head of household
Hollingshead occupational level and socio-
economic score (Hollingshead 1958)].
Analyses. We initially compared the
covariates between subjects by cumulative lead
exposure status (i.e., low vs. high). Because age
and weight are strongly associated with BMD,
we decided, a priori, to introduce both into
adjusted analyses. Other comparisons with
p-values ≤ 0.20 were also to be introduced
into adjusted analyses. The primary analysis
was, for each bony site, a comparison of the
mean BMD by cumulative lead exposure sta-
tus. Using SPSS software (version 4.0; SPSS
Inc., Chicago, IL), we conducted adjusted
analyses by use of analysis of covariance
between the cumulative lead exposure groups.
A sample size calculation demonstrated
that 44 subjects would be required to achieve
a power of 80% in discerning a 1.0-SD
difference in BMD between the groups. We
conducted analyses during subject recruit-
ment, thus allowing us to discontinue enroll-
ment after signiﬁcant ﬁndings were discerned
at a sample size of 35 subjects.
Results
We collected data on 36 subjects. All were
African American. One subject was excluded
because of obesity [body mass index (BMI) =
33]. Among the remaining subjects, 63%
were male. The mean age was 109.5 months.
The mean weight was 33.6 kg, and the mean
height 138.6 cm; these measures are approxi-
mately at the 75th and 60th percentiles,
respectively.
Among the 35 subjects analyzed, 16 had a
low cumulative lead exposure and 19 had a high
cumulative lead exposure; the respective mean
cumulative lead exposures were 6.5 µg/dL
(range, 2.7–10.3 µg/dL) and 23.6 µg/dL (range,
15.5–43.5 µg/dL) (Table 1). The groups were
otherwise comparable; there were no differ-
ences (i.e., p > 0.20) between the groups on sex
distribution, age, BMI, socioeconomic status,
physical activity, or calcium intake (Table 2).
Table 3 shows the adjusted mean BMD by
bony site and cumulative lead exposure status.
Contrary to our hypothesis, we found that sub-
jects with high cumulative lead exposure had a
higher BMD than did subjects with low cumu-
lative lead exposure. Among 17 bony sites, four
were signiﬁcantly different (i.e., p ≤ 0.05).
Discussion
Contrary to our hypothesis, we found that sub-
jects with high lead exposure had a signiﬁcantly
higher bone density than did subjects with low
lead exposure. We initially considered whether
this result derived from an artiﬁcial increase in
the measure of bone density by DEXA due to
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Table 1. Blood lead level measures by cumulative
lead exposure status [low vs. high (µg/dL)].
BLL measure Low High
Mean BLL
12–23 months 7.3 23.8
24–35 months 7.4 22.4
36–47 months 5.4 24.5
48–60 months 4.9 21.1
Mean cumulative lead exposurea 6.5 23.6
Range 2.7–10.3 15.5–43.5
BLL, blood lead level.
aDeﬁned in ”Materials and Methods.”
Table 2. Comparison of covariates by cumulative lead exposure status (low vs. high).
Covariates Low High p-Valuea
Demographics
Sex (% male) 56 68 0.46
Age (months) 109.9 109.2 0.73
HOH Hollingshead occupation levelb 5.6 6.3 0.30c
HOH Hollingshead socioeconomic scoreb 89.4 89.7 0.92
Body size
Weight (kg) 34.1 33.2 0.72
Height (cm) 137.4 139.6 0.40
BMI (kg/m2) 17.9 16.9 0.28
Physical activity
Active play (hr/day) 4.8 4.6 0.80
Inactive play (hr/day) 3.2 3.0 0.72
Calcium intake (portions/day) 3.6 3.6 1.00
HOH, head of household.
aBy t-test, except where speciﬁed. bHOH Hollingshead occupation level and socioeconomic level (Hollingshead 1958). cBy
Mann-Whitney U-statistic.
Table 3. Adjusted BMD (g/cm2) by bony site and
cumulative lead exposure (low vs. high).
BMD site Low High p-Valuea
Body regions
Head 1.589 1.721 < 0.01**
Arms 0.684 0.704 0.16
Legs 0.917 0.928 0.61
Trunk 0.693 0.720 0.06*
Ribs 0.594 0.615 0.09*
Pelvis 0.806 0.839 0.09*
Spine 0.720 0.749 0.14
Total body 0.911 0.940 0.06*
Lumbar vertebrae
L1b 0.682 0.707 0.28
L2 0.722 0.756 0.22
L3 0.761 0.819 0.01**
L4 0.712 0.789 0.01**
L1–L4 0.720 0.770 0.03**
Hip regions
Femoral neck 0.827 0.893 0.07*
Trochanter 0.682 0.732 0.11
Femoral shaft 0.939 1.006 0.11
Total hip 0.842 0.906 0.08*
aBy analysis of covariance. bFirst lumbar vertebra.
*Marginally significant (i.e., 0.05 < p < 0.10). **Significant
at p ≤ 0.05 level.the presence of lead in bone. A false elevation
of DEXA-based bone density is reported to
occur in bone containing strontium, a heavy
metal with a lower atomic weight than lead
(Nielsen et al. 1999). We found, in an in vitro
study using an older Lunar DPX-L pencil-
beam instrument, that bone density increased
by 8–11% with increasing and clinically rele-
vant bone lead levels (i.e., 10–100 µg/g) (Puzas
et al. 2002). However, when this in vitro study
was replicated using a newer Lunar Prodigy
fan-beam instrument, the same used on the
subjects of our study, the effect was minimal
and within the precision of the DEXA measure
(Muzytchuk et al. 2004).
The alternative interpretation of our ﬁnd-
ings is that high lead exposure is associated
with truly higher bone density in childhood.
Our results indicate that the magnitude of this
association is clinically relevant. For example,
the mean BMD of the lumbar vertebrae
(L1–L4) was 0.770 g/cm2 versus 0.720 g/cm2
among subjects with high and low cumulative
lead exposure, respectively (p = 0.03). Thus, in
this study, children with high cumulative lead
exposure had nearly 7% higher BMD at the
lumbar vertebrae than did children with low
cumulative lead exposure. This amounts to
about 2 years of bone growth.
We now wish to speculate on the mecha-
nism of this ﬁnding. An in vitro study found
that lead inhibits parathyroid hormone–related
peptide (PTHrP) and transforming growth
factor-β1, proteins that decrease the rate of
maturation of chondrocytes in endochondral
bone formation (Zuscik et al. 2002). Further,
this inhibition of PTHrP is associated with
accelerated skeletal maturity. Mice homo-
zygous for PTHrP gene deletion have advanced
skeletal maturation at birth (Karaplis et al.
1994; Lee et al. 1996). Similarly, children with
Blomstrand syndrome, a congenital chon-
drodysplasia due to nonfunctioning PTHrP
receptors (Jobert et al. 1998; Karaplis et al.
1998), also have advanced skeletal maturation
and higher than normal bone density at birth
(Blomstrand et al. 1985; den Hollander
et al. 1997; Loshkajian et al. 1997; Young
et al. 1993). The inhibition of PTHrP causes
premature maturation of the chondrocytes
(Zuscik et al. 2002), which may result in a
higher bone density.
Our findings differ from past research
ﬁndings that lead exposure is associated with
lower, not higher, bone density in mature ani-
mals (Escribano et al. 1997; Gruber et al.
1997; Puzas et al. 1999; Ronis et al. 2001).
Nevertheless, the literature suggests that the
higher bone density associated with PTHrP
inhibition is transient. Although mice homo-
zygous for PTHrP gene deletion have higher
bone density at birth (Karaplis et al. 1994),
mice heterozygous for PTHrP gene deletion
have osteopenia as adults (Amizuka et al.
1996; He et al. 2000). The proposed mecha-
nism is as follows: Besides its effects on endo-
chondral bone formation, PTHrP also acts on
bone remodeling in adult organisms. It pro-
motes the differentiation of bone marrow
stem cells toward osteoblasts and away from
adipocytes and impedes the apoptosis of
osteoblasts (Karaplis 2001). In a mature
organism without endochondral bone forma-
tion, PTHrP inhibition on bone remodeling
would predominate—that is, differentiation
of stem cells toward adipocytes and an
increased rate of osteoblast apoptosis—thus
predisposing to osteoporosis (Karaplis et al.
2001). We therefore speculate that a lead-
exposed individual may undergo a higher rate
of bone loss when older than would individu-
als without lead exposure.
An alternative model for the development
of osteoporosis is that a lead-exposed individual
may achieve a lower peak bone mass as a young
adult. Studies of children have found a negative
association between blood lead level and height
(Ballew et al. 1999; Schwartz et al. 1986;
Selevan et al. 2003). Similarly, mice homo-
zygous for PTHrP gene deletion, in addition to
having advanced skeletal maturation, have
shorter long bones and shorter vertebrae than
do normal mice (Karaplis et al. 1994). These
ﬁndings along with the ﬁndings described in
the preceding paragraph suggest that lead tar-
gets its effects on the growth plate by inhibiting
PTHrP and thus causing shorter stature in
exposed children. We speculate that this inhibi-
tion of stature when young results in a lower
peak bone mass being achieved, thus predispos-
ing to osteoporosis in later life (Figure 1).
Future studies are needed to investigate whether
these proposed models are valid.
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Figure 1. This study found that bone density for
lead-exposed children is higher than that for chil-
dren not exposed to lead. We propose that this
increase may be transient (inset). A lower peak
bone mass may occur in early adulthood (B rather
than A), thus predisposing to osteoporosis in later
life (D rather than C).
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